Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Gupta, B., Kumar, N
We're diagnosing these people at stages where they're not curable, Gitlitz explains
CMS believes these proposals on treatment of missing pricing data and treatment of pricing differences between reported prices and the published payment limit for a billing and payment code will further clarify the application of the specified amount in the calendar quarter are consistent with the requirements set forth in section 1847A(i)(3)(A)(ii)(I) of the Act
We are also proposing to codify that in cases where negative or zero manufacturer's ASP data is reported for some, but not all, NDCs of a biosimilar, we would calculate the payment limit using the positive manufacturer's ASP data reported for the biosimilar
US$ 22.89
US$ 27.08
US$ 21.01
US$ 27.34
